Drug Approval | July 27, 2025
Alembic Pharmaceuticals announces USFDA final approval for Carbamazepine ER Tablets USP
Carbamazepine Extended-Release Tablets are indicated for use as an anticonvulsant drug
Carbamazepine Extended-Release Tablets are indicated for use as an anticonvulsant drug
This GMP certification for our sterile drug product manufacturing facility, Goa Plant II is a testament to our relentless efforts to supply quality and affordable medicines across geographies
The scheme aims to avoid disruption in supply of critical active pharmaceutical ingredients (APIs) used to make critical drugs
Both these products will be manufactured at Lupin’s Injectable facility at Nagpur, India
The coating is designed for heat-sealable applications, offering oil and grease resistance on kraft paper and suitable blister coatings for paper and paperboard
Investment will support AstraZeneca’s ambition to reach $80 billion revenue by 2030, with 50% generated in the US
Based on the CRL, the STARGLO data do not provide sufficient evidence to support the proposed second-line DLBCL indication in the US patient population
FDA requests Sarepta Therapeutics to suspend distribution of Elevidys and places clinical trials on hold for multiple gene therapy products following 3 deaths
During Q1FY26, the company incurred Capex of ~Rs. 48.5 crores mainly towards capacity expansion, backward integration and finished formulation R&D
Investment builds on Biogen’s 30-year history of manufacturing in the region, with approximately $10 billion invested to date
Subscribe To Our Newsletter & Stay Updated
